Company News

Connect with us at BIO-Europe Spring 2021!

Kelun-Biotech and Ellipses Pharma Announce a Licensing Agreement for A400

Sichuan Kelun-Biotech Pharmaceutical Co., Ltd. and UK company Ellipses Pharma Ltd. Announce a Licensing Agreement for Innovative Small Molecule Cancer Therapeutics

Image-empty-state.png

KLUS Pharma is Attending BIO-Europe Spring

KLUS Pharma will attend BIO-Europe Spring Digital Event held on March 22-25, 2021.

Image-empty-state.png

KLUS Pharma is Attending BIO Partnering at JPM

KLUS Pharma will attend BIO Partnering at JPM Digital Event held on January 11-15, 2021.

Image-empty-state.png

IND for KL-A289 is Approved in China

The IND for KL-A289, an anti-LAG-3 monoclonal antibody, was recently approved by the NMPA in China.

Image-empty-state.png

Looking for Partnerships to Combat COVID-19

We are looking for partnerships to develop and distribute ACV200-17, a peptide drug to prevent COVID-19, in affected countries.

Image-empty-state.png

KLUS Pharma to Present at BIO Digital

KLUS Pharma will present an update for SKB264, a novel TROP2 ADC, at BIO Digital Event held on June 8-12, 2020.

Image-empty-state.png

©2021 by KLUS Pharma Inc.